Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 104.85B |
| Revenue (ttm) | 9.65B |
| Net Income (ttm) | 3.47B |
| Shares Out | 257.68M |
| EPS (ttm) | 13.32 |
| PE Ratio | 30.55 |
| Forward PE | 23.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 727,543 |
| Open | 409.00 |
| Previous Close | 409.27 |
| Day's Range | 406.07 - 409.62 |
| 52-Week Range | 282.21 - 413.00 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 375.16 (-7.8%) |
| Earnings Date | Feb 6, 2024 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company'... [Read more]
Financial Performance
In 2022, VRTX's revenue was $8.93 billion, an increase of 17.91% compared to the previous year's $7.57 billion. Earnings were $3.32 billion, an increase of 41.84%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $375.16, which is a decrease of -7.80% from the latest price.
News
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 42nd Annual J.P. Mor...
Wells Fargo's top pharma picks for 2024
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopt...
Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal
Vertex Pharmaceuticals (VRTX) shares hit at an all-time high Wednesday after reporting promising results from a study of its experimental treatment to reduce pain in diabetics, and striking a deal for...
Stock Movers: J&J, Vertex Pharma and Tesla
The “Halftime Report” Investment Committee debate the market movers they own.
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
The results support Vertex's hopes of developing a drug that can provide strong pain relief without the addictive potential of opioid medications.
Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss
U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to...
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with...
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced two oral presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition from the gl...
Sickle cell gene editing faces market hurdles: Analyst
"The FDA approved a gene editing treatment for sickle cell disease to alleviate severe, recurrent pain crises. Casgevy, developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), is a ...
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR...
Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.
Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln
Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy Casgevy would be available at a list price of $2.2 million in the United States.
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease
CNBC's Angelica Peebles reports on the latest news in bioscience.
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) h...
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment
Crispr Therapeutics AG CRSP, -5.37% and Vertex Pharmaceuticals Inc. VRTX, -1.25% on Friday got U.S. regulatory approval for a treatment for sickle-cell disease based on the transformative gene-editing...
CRISPR, VRTX stock prices waver as US FDA approves Casgevy
The Crispr Therapeutics (NASDAQ: CRSP) stock price moved sideways after the Food and Drug Administration (FDA) approved Casgevy. The shares were trading at $70.30 on Friday, where they have been in th...
US approves two gene therapies for sickle cell disease
The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.
U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
Vertex Appoints Nancy Thornberry to its Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberr...
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration